Danzon Patricia M 4
4 · MEDAREX INC · Filed Sep 3, 2009
Insider Transaction Report
Form 4
MEDAREX INCMEDX
Danzon Patricia M
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2009-09-01$16.00/sh−18,000$288,000→ 0 totalExercise: $14.92Exp: 2017-05-17→ Common Stock (18,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2009-09-01$16.00/sh−30,000$480,000→ 0 totalExercise: $7.76Exp: 2015-05-18→ Common Stock (30,000 underlying) - Disposition to Issuer
Restricted Stock Units
2009-09-01$16.00/sh−3,161$50,576→ 0 total→ Common Stock (3,161 underlying) - Disposition to Issuer
Restricted Stock Units
2009-09-01$16.00/sh−6,721$107,536→ 0 total→ Common Stock (6,721 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2009-09-01$16.00/sh−18,000$288,000→ 0 totalExercise: $7.91Exp: 2018-05-14→ Common Stock (18,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2009-09-01$16.00/sh−18,000$288,000→ 0 totalExercise: $3.72Exp: 2019-03-04→ Common Stock (18,000 underlying)
Footnotes (8)
- [F1]This option was canceled in the merger in exchange for a cash payment of $19,530.00, reprsenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F2]This option was canceled in the merger in exchange for a cash payment of $145,620.00, reprsenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F3]This option was canceled in the merger in exchange for a cash payment of $247,200.00, reprsenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F4]This option was canceled in the merger in exchange for a cash payment of $221,040.00, reprsenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F5]This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of $50,576.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F6]This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of $107,536.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- [F7]Each restricted stock unit represents a contingent right to receive one (1) share of Medarex, Inc. common stock
- [F8]The Restricted Stock Units vested ratably on each of the first, second and third anniversaries of the grant date and the receipt of the shares of common stock was deferred until the individual's retirement or separation of service from the Board.